세계의 약물 모델링 소프트웨어 시장 예측(-2030년) : 구성 요소별, 배포, 운영 체제별, 기업 규모별, 구매 모델별, 용도별, 최종 사용자별, 지역별 분석

According to Stratistics MRC, the Global Drug Modeling Software Market is accounted for $7.7 billion in 2023 and is expected to reach $15.5 billion by 2030 growing at a CAGR of 10.5% during the forecast period Drug Modeling Software refers to computational tools employing algorithms and simulations to predict, analyze and optimize aspects of drug discovery and development. These programs facilitate the understanding of molecular interactions, pharmacokinetics and drug-target interactions. By simulating and modeling biological systems, chemical structures and drug behavior, they aid in designing, screening and optimizing potential drug candidates, enhancing the efficiency and success rates of pharmaceutical research and development processes.

According to the Pharmaceutical Research and Manufacturers of America, a successful drug's research and development cost an average of US$2.6 BN.

Market Dynamics:

Driver:

Growing need for novel treatments

With an increasing prevalence of complex diseases and evolving therapeutic requirements, there's a pressing need for innovative and effective treatments. Drug modeling software enables the exploration of diverse molecular structures and predictive simulations, expediting the identification and optimization of potential drug candidates. This technology-driven approach not only accelerates the discovery process but also aids in designing tailored therapies, meeting the demand for more precise, targeted and efficacious treatments, consequently propelling the software's significance and adoption in advancing healthcare innovation.

Restraint:

Validation and precision challenges

Ensuring the accuracy and reliability of predictive models requires extensive validation against experimental data, often demanding substantial time and resources. Additionally, complex biological systems and the diverse interactions between drugs and targets contribute to precision challenges, impacting the software's predictive capabilities. The limitations of accurately replicating real-world complexities hinder the software's effectiveness, necessitating continuous refinement and validation efforts.

Opportunity:

Rising interest in cloud-based analytics and data processing

Cloud platforms offer scalable, cost-effective infrastructure capable of handling vast datasets and complex computations. This shift allows for enhanced collaboration, faster processing speeds and greater accessibility to sophisticated modeling tools. Moreover, cloud-based solutions facilitate seamless integration with other applications and enable real-time data sharing among researchers globally. Embracing this trend not only streamlines workflows but also fosters innovation, empowering organizations to leverage cutting-edge technologies and drive advancements in drug discovery and development while optimizing costs and resource utilization.

Threat:

Data privacy and security concerns  

Data privacy and security concerns pose a significant threat to the drug modeling software market. The sensitive nature of patient data and proprietary information in drug development raises apprehensions about potential breaches, unauthorized access or data misuse. Instances of security lapses could erode trust, impact adoption rates, and hinder collaboration between pharmaceutical entities and software providers. Moreover, stringent regulations like GDPR and HIPAA impose rigorous standards for handling healthcare data, augmenting the pressure on software developers to ensure compliance.

COVID-19 Impact:

The COVID-19 pandemic accelerated the adoption of drug modeling software, intensifying its role in remote drug development and virtual clinical trials. It prompted a heightened reliance on predictive analytics and computational methods for rapid drug design and repurposing, facilitating faster responses to emerging health crises. However, disruptions in research and clinical activities temporarily affected market growth. Yet, the pandemic underscored the software's criticality, spurring innovation and reinforcing its pivotal role in agile and remote drug development processes.

The hospitals & healthcare providers segment is expected to be the largest during the forecast period

The hospitals and healthcare providers segment is anticipated to lead the drug modeling software market due to its increasing leverage of advanced software for personalized treatment strategies, drug efficacy predictions and treatment optimization. With a focus on precision medicine, hospitals and healthcare providers utilize drug modeling software for clinical decision support, enhancing patient care outcomes. Additionally, the integration of these tools into electronic health records facilitates seamless implementation, contributing to the segment's dominance.

The drug discovery and development segment is expected to have the highest CAGR during the forecast period

The drug discovery and development segment is poised for significant growth owing to the continuous surge in demand for novel therapeutics. Drug developers increasingly rely on advanced modeling software to expedite the identification, design and optimization of potential drug candidates. Additionally, the integration of artificial intelligence and machine learning further enhances efficiency, driving the substantial anticipated growth of this segment within the drug modeling software market.

Region with largest share:

North America is anticipated to lead the drug modeling software market due to its robust pharmaceutical and biotech sectors. The region boasts significant R&D investments, advanced healthcare infrastructure and a strong presence of major industry players. Moreover, the region's emphasis on innovation and technology adoption, coupled with a high demand for personalized medicine and precision drug development, drives the use of sophisticated modeling software. These factors, combined with supportive regulatory frameworks and a culture of early adoption of novel technologies, position North America to dominate the drug modeling software market.

Region with highest CAGR:

Asia Pacific is poised for substantial growth in the drug modeling software market due to the region's burgeoning pharmaceutical and biotech industries, coupled with increasing R&D investments. Additionally, the presence of a vast patient pool for clinical trials and a growing emphasis on precision medicine foster the adoption of drug modeling software. Moreover, expanding healthcare infrastructure, technological advancements and supportive government initiatives propel growth in this region.

Key players in the market:

Some of the key players in drug modeling software market include Acellera, Biovia, Certara, Chemical Computing Group, Collaborative Drug Discovery, Inc., Cresset, Genedata AG, Insilico Medicine, Instinctools GmbH, Leadscope, Inc., Molecular Networks GmbH, Nimbus Therapeutics, Numerate, Inc., OpenEye Scientific Software, Optibrium Ltd., Pharmacelera, Physiomics plc, Schrodinger, Inc. and Simulations Plus, Inc.

Key Developments:

In May 2023, Cresset announced the latest release of molecular modeling platform that delivers improved efficiencies for small molecule discovery therefore Flare V7. This helps the organisation developing more revenue.

In May 2023, Fujitsu launched the Biodrug Design Accelerator platform to increase peptide drug discovery research. This platform helps peptide drug discovery scientists in pharmaceutical industries to speed up and increases the efficiency of peptide drug development, especially through the cycles "design, make, test, analyze" (DMTA), ultimately allowing faster and informed design of peptide drug candidates and effective communication among scientists about synthesis and testing.

In February 2023, Accenture has made a strategic investment, through Accenture Ventures, in Ocean Genomics, a technology and AI company that has developed advanced computational platforms to assist biopharma companies to discover and develop more effective diagnostics and therapeutics.

Components Covered:

• Software
• Database

Deployments Covered:

• Cloud Based
• Hybrid-Based
• On-Premises

Operating Systems Covered:

• Windows
• Linux
• Mac Os
• Other Operating Systems

Enterprise Sizes Covered:

• Large Enterprise Size
• Small & Medium Enterprise Size

Purchasing Models Covered:

• Subscription Based
• One-Time License

Applications Covered:

• Cellular Simulation
• Cheminformatics
• Disease Modeling
• Drug Discovery and Development
• Gene Sequence Analysis
• Graphical Molecular Modeling
• Medical Imaging
• Protein Modeling
• Other Applications

End Users Covered:

• Contract Research Organizations (CROs)
• Pharmaceutical & Biotechnology Companies
• Hospitals & Healthcare Providers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Drug Modeling Software Market, By Component

• 5.1 Introduction
• 5.2 Software
• 5.3 Database

6 Global Drug Modeling Software Market, By Deployment

• 6.1 Introduction
• 6.2 Cloud Based
• 6.3 Hybrid-Based
• 6.4 On-Premises

7 Global Drug Modeling Software Market, By Operating System

• 7.1 Introduction
• 7.2 Windows
• 7.3 Linux
• 7.4 Mac Os
• 7.5 Other Operating Systems

8 Global Drug Modeling Software Market, By Enterprise Size

• 8.1 Introduction
• 8.2 Large Enterprise Size
• 8.3 Small & Medium Enterprise Size

9 Global Drug Modeling Software Market, By Purchasing Model

• 9.1 Introduction
• 9.2 Subscription Based
• 9.3 One-Time License

10 Global Drug Modeling Software Market, By Application

• 10.1 Introduction
• 10.2 Cellular Simulation
• 10.3 Cheminformatics
• 10.4 Disease Modeling
• 10.5 Drug Discovery and Development
• 10.6 Gene Sequence Analysis
• 10.7 Graphical Molecular Modeling
• 10.8 Medical Imaging
• 10.9 Protein Modeling
• 10.10 Other Applications

11 Global Drug Modeling Software Market, By End User

• 11.1 Introduction
• 11.2 Contract Research Organizations (CROs)
• 11.3 Pharmaceutical & Biotechnology Companies
• 11.4 Hospitals & Healthcare Providers
• 11.5 Other End Users

10 Global Drug Modeling Software Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Acellera
• 12.2 Biovia
• 12.3 Certara
• 12.4 Chemical Computing Group
• 12.5 Collaborative Drug Discovery, Inc.
• 12.6 Cresset
• 12.7 Genedata AG
• 12.8 Insilico Medicine
• 12.9 Instinctools GmbH
• 12.10 Leadscope, Inc.
• 12.11 Molecular Networks GmbH
• 12.12 Nimbus Therapeutics
• 12.13 Numerate, Inc.
• 12.14 OpenEye Scientific Software
• 12.15 Optibrium Ltd.
• 12.16 Pharmacelera
• 12.17 Physiomics plc
• 12.18 Schrodinger, Inc.
• 12.19 Simulations Plus, Inc.